AR012751A1 - Sales de hidrogeno tartrato de (r) -3-n,n-diciclobutilamino-8-fluoro-3,4 -dihidro-2h-1-benzopiran-5-carboxamida, su uso para la fabricacion de medicamentos para tratar trastornos de snc y trastornos medicos relacionados y procedimiento para la fabricacion de dichas sales - Google Patents

Sales de hidrogeno tartrato de (r) -3-n,n-diciclobutilamino-8-fluoro-3,4 -dihidro-2h-1-benzopiran-5-carboxamida, su uso para la fabricacion de medicamentos para tratar trastornos de snc y trastornos medicos relacionados y procedimiento para la fabricacion de dichas sales

Info

Publication number
AR012751A1
AR012751A1 ARP980102434A ARP980102434A AR012751A1 AR 012751 A1 AR012751 A1 AR 012751A1 AR P980102434 A ARP980102434 A AR P980102434A AR P980102434 A ARP980102434 A AR P980102434A AR 012751 A1 AR012751 A1 AR 012751A1
Authority
AR
Argentina
Prior art keywords
manufacture
salts
tartrate
disorders
fluoro
Prior art date
Application number
ARP980102434A
Other languages
English (en)
Original Assignee
Astrazeneca Ab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Astrazeneca Ab filed Critical Astrazeneca Ab
Publication of AR012751A1 publication Critical patent/AR012751A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D311/00—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only hetero atom, condensed with other rings
    • C07D311/02—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only hetero atom, condensed with other rings ortho- or peri-condensed with carbocyclic rings or ring systems
    • C07D311/04—Benzo[b]pyrans, not hydrogenated in the carbocyclic ring
    • C07D311/58—Benzo[b]pyrans, not hydrogenated in the carbocyclic ring other than with oxygen or sulphur atoms in position 2 or 4
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/14—Prodigestives, e.g. acids, enzymes, appetite stimulants, antidyspeptics, tonics, antiflatulents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/04—Drugs for disorders of the urinary system for urolithiasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/06—Antimigraine agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives

Landscapes

  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Psychiatry (AREA)
  • Pain & Pain Management (AREA)
  • Urology & Nephrology (AREA)
  • Cardiology (AREA)
  • Child & Adolescent Psychology (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Hospice & Palliative Care (AREA)
  • Nutrition Science (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)

Abstract

Una nueva sal de hidrogeno tartrato de (R)-3-N,N-diciclobutilamino-8-fluoro -3,4-dihidro-2H-1-benzopiran-5-carboxamida, particularmente su (2R; 3R)-tartrato, más particularmente el monohidrato de hidrogeno (2R, 3R) tartrato de (R)-3-N,N-diciclobutilamino-8-fluoro-3,4-dihidro-2H-1 benzopiran-5-carboxamida, los procesos para la fabricacion de dicha sal de tartrato, el uso de la sal en medicina, el uso de la sal de tartrato en la fabricacion deformulaciones farmacéuticas y un método para el tratamiento de los trastornos del SNC por la administracion de la sal de tartrato a un huésped quenecesita dicho tratamiento.
ARP980102434A 1997-05-30 1998-05-26 Sales de hidrogeno tartrato de (r) -3-n,n-diciclobutilamino-8-fluoro-3,4 -dihidro-2h-1-benzopiran-5-carboxamida, su uso para la fabricacion de medicamentos para tratar trastornos de snc y trastornos medicos relacionados y procedimiento para la fabricacion de dichas sales AR012751A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
SE9702066A SE510305C2 (sv) 1997-05-30 1997-05-30 Nytt salt

Publications (1)

Publication Number Publication Date
AR012751A1 true AR012751A1 (es) 2000-11-08

Family

ID=20407187

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP980102434A AR012751A1 (es) 1997-05-30 1998-05-26 Sales de hidrogeno tartrato de (r) -3-n,n-diciclobutilamino-8-fluoro-3,4 -dihidro-2h-1-benzopiran-5-carboxamida, su uso para la fabricacion de medicamentos para tratar trastornos de snc y trastornos medicos relacionados y procedimiento para la fabricacion de dichas sales

Country Status (34)

Country Link
US (2) US6858645B2 (es)
EP (1) EP0984952B1 (es)
JP (1) JP3554338B2 (es)
KR (1) KR20010013127A (es)
CN (1) CN1198814C (es)
AR (1) AR012751A1 (es)
AT (1) ATE228121T1 (es)
AU (1) AU729301B2 (es)
BG (1) BG64051B1 (es)
BR (1) BR9809519A (es)
CA (1) CA2291732C (es)
DE (1) DE69809547T2 (es)
DK (1) DK0984952T3 (es)
EE (1) EE03874B1 (es)
ES (1) ES2187030T3 (es)
HK (1) HK1025575A1 (es)
HU (1) HUP0001878A3 (es)
ID (1) ID23794A (es)
IL (1) IL133234A (es)
IS (1) IS1943B (es)
MY (1) MY117960A (es)
NO (1) NO995853L (es)
NZ (1) NZ501075A (es)
PL (1) PL337181A1 (es)
PT (1) PT984952E (es)
RU (1) RU2193560C2 (es)
SE (1) SE510305C2 (es)
SK (1) SK282755B6 (es)
TR (1) TR199902926T2 (es)
TW (1) TW510899B (es)
UA (1) UA53720C2 (es)
WO (1) WO1998054166A1 (es)
YU (1) YU62499A (es)
ZA (1) ZA984486B (es)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SE0102888D0 (sv) * 2001-08-29 2001-08-29 Astrazeneca Ab New formulation
SE0102886D0 (sv) * 2001-08-29 2001-08-29 Astrazeneca Ab New formulation
SE0102887D0 (sv) * 2001-08-29 2001-08-29 Astrazeneca Ab New formulation
SE0301796D0 (sv) * 2003-06-19 2003-06-19 Astrazeneca Ab New use II
SE0301795D0 (sv) * 2003-06-19 2003-06-19 Astrazeneca Ab New use I
ATE528807T1 (de) * 2006-05-11 2011-10-15 Johnson Controls Saft Advanced Power Solutions Llc Modulares batteriesystem
JP5163931B2 (ja) * 2007-03-08 2013-03-13 株式会社リコー 定着装置及び画像形成装置
EP2065385A1 (en) * 2007-11-28 2009-06-03 Laboratorios SALVAT, S.A. Stable crystalline salt of (R)-3-fluorophenyl-3,4,5-trifluorobenzylcarbamic acid 1-azabiciyclo [2.2.2]oct-3-yl ester
CN103833712B (zh) * 2008-11-28 2016-02-03 中国医学科学院药物研究所 硝克柳胺化合物晶ii型、其制法和其药物组合物与用途
KR102388926B1 (ko) * 2013-04-26 2022-04-22 베이징 리앤신 파마수티컬 씨오., 엘티디. 5-클로로-티오펜-2-카복실산 [(s)-2-[메틸-3-(2-옥소-피롤리딘-1-일)-벤젠설포닐아미노]-3-(4-메틸 피페라진-1-일)-3-옥소-프로필]아미드의 타르트레이트 염

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5616610A (en) * 1989-12-22 1997-04-01 Astra Aktiebolag (R)-5-carbamoyl-8-fluoro-3-N,N-disubstituted-amino-3,4-dihydro-2H-1-benzopyrans
US5420151A (en) * 1989-12-22 1995-05-30 Aktiebolaget Astra Chroman derivatives
IT1282705B1 (it) 1996-02-28 1998-03-31 Recordati Chem Pharm Uso di antagonisti del recettore serotoninergico 5-ht|a per il trattamento dell'incontinenza urinaria
US5990114A (en) * 1996-02-28 1999-11-23 Recordati, S.A., Chemical And Pharmaceutical Company Use of 5-HT1A receptor antagonists for the treatment of urinary incontinence

Also Published As

Publication number Publication date
EP0984952B1 (en) 2002-11-20
DK0984952T3 (da) 2003-02-24
ZA984486B (en) 1998-11-30
DE69809547D1 (de) 2003-01-02
BR9809519A (pt) 2000-06-20
US6858645B2 (en) 2005-02-22
JP3554338B2 (ja) 2004-08-18
TW510899B (en) 2002-11-21
EE03874B1 (et) 2002-10-15
PL337181A1 (en) 2000-08-14
AU729301B2 (en) 2001-02-01
CN1198814C (zh) 2005-04-27
ES2187030T3 (es) 2003-05-16
BG64051B1 (bg) 2003-11-28
SK159499A3 (en) 2000-10-09
AU7792398A (en) 1998-12-30
HK1025575A1 (en) 2000-11-17
NO995853D0 (no) 1999-11-29
EP0984952A1 (en) 2000-03-15
CA2291732C (en) 2003-12-30
NZ501075A (en) 2001-08-31
YU62499A (sh) 2002-06-19
UA53720C2 (uk) 2003-02-17
WO1998054166A1 (en) 1998-12-03
PT984952E (pt) 2003-03-31
IS1943B (is) 2004-08-13
CN1258290A (zh) 2000-06-28
MY117960A (en) 2004-08-30
NO995853L (no) 2000-01-31
TR199902926T2 (xx) 2000-03-21
SE9702066D0 (sv) 1997-05-30
ATE228121T1 (de) 2002-12-15
IL133234A0 (en) 2001-03-19
BG103949A (en) 2000-07-31
JP2002501527A (ja) 2002-01-15
CA2291732A1 (en) 1998-12-03
KR20010013127A (ko) 2001-02-26
RU2193560C2 (ru) 2002-11-27
HUP0001878A3 (en) 2002-04-29
HUP0001878A2 (hu) 2001-05-28
SK282755B6 (sk) 2002-12-03
SE510305C2 (sv) 1999-05-10
IL133234A (en) 2004-05-12
IS5270A (is) 1999-11-24
ID23794A (id) 2000-05-11
EE9900549A (et) 2000-06-15
DE69809547T2 (de) 2003-08-21
US20030109576A1 (en) 2003-06-12
SE9702066L (sv) 1998-12-01
US20050085532A1 (en) 2005-04-21

Similar Documents

Publication Publication Date Title
CO5670327A2 (es) Procedimiento para el tratamiento de trastornos de depresion y ansiedad mediante terapia de combinacion
HUP0203325A2 (hu) Biciklusos aminosavak, ezeket tartalmazó gyógyszerkészítmények és alkalmazásuk
ECSP055738A (es) PROCESO ENANTIOSELECTIVO PARA LA PREPARACIÓN DE AMBOS ENANTIÓMEROS DE 10,11-DIHIDRO-10-HIDROXI-5H-DIBENZ-[b,f]-AZEPIN-5-CARBOXAMIDA Y SUS NUEVAS FORMAS DE CRISTAL
BR0009042A (pt) Composto, uso do mesmo, processo para prepararum composto, composição farmacêutica, e, métodospara tratar uma doença em um animal em que aatividade de cisteìna protease contribui para apatologia e/ou sintomatologia da doença, e paratratar uma doença em um animal em que a atividadede catepsina s contribui para a patologia e/ousintomatologia da doença
ES2164040T1 (es) Uso de agonistas del sitio de union de la glicina o de inhibidores de la absorcion de la glicina para el tratamiento de trastornos neuropsiquiatricos.
ES2145913T3 (es) Inhibidores de metaloproteasas.
PT913156E (pt) Utilizacao de proteina c activada para tratar estados hipercoagulaveis associados com sepsia
DK1346041T3 (da) Terapeutiske midler og fremgangsmåder til anvendelse deraf til behandling af en amyloidogen sygdom
RU94022479A (ru) Применение антиэстрогенных соединений, а также фармацевтически приемлемых солей и сольватов для уменьшения концентрации глюкозы в крови, фармацевтический препарат
AR019853A1 (es) Derivado del acido 3-aril-2-hidroxipropionico, proceso e intermediario para su preparacion, formulaciones farmaceuticas, uso de dicho compuesto en laelaboracion de un medicamento, metodo para la profilaxis y/o tratamiento de trastornos clinicos asociados con la resistencia a la insulina, y formulaci
AR012751A1 (es) Sales de hidrogeno tartrato de (r) -3-n,n-diciclobutilamino-8-fluoro-3,4 -dihidro-2h-1-benzopiran-5-carboxamida, su uso para la fabricacion de medicamentos para tratar trastornos de snc y trastornos medicos relacionados y procedimiento para la fabricacion de dichas sales
DK1546127T3 (da) Nye pyrimidinamidderivater og anvendelse deraf
AR024998A1 (es) Nuevos retinoides para el tratamiento del enfisema
AR066455A2 (es) Uso de compuestos n-metil-n-[(1r)-1-fenil-2-(3r)-3-hidroxipirrolidin -1-il-=-etil]-2,2-difenilacetamida para producir un medicamento para el tratamiento de emfermedades intestinales no inflamatorias
ES2064166T3 (es) Composiciones conteniendo propionato de fluticasona y oxiconazol o sus sales para administracion topica.
DK1091733T3 (da) (-)-Pseudoephedrin som et sympatomimetisk lægemiddel
PA8517701A1 (es) Combinacion de secretagogos de hormona del crecimiento y antidepresivos
AR001769A1 (es) Benzamida enterocinética composiciones farmacéuticas que las contienen procedimiento para la preparación de dichas composiciones farmacéuticas el uso de dichos compuestos para la manufactura de medicamentos y un procedimiento para su preparación
RU94040886A (ru) Применение производных мелатонина для лечения нарушений сна, фармацевтическая композиция
DK0494817T3 (da) Benzisoxazol- og benzisothiazolderivater, fremgangsmåde til fremstilling heraf og farmaceutiske midler, som indeholder dem
MX9400040A (es) Composiciones para tratar trastornos respiratorios.
HUP0300863A2 (hu) N-(3,5-diklór-2-metoxi-fenil)-4-metoxi-3-(1-piperazinil)-benzolszulfonamid, eljárás elżállítására és a vegyületet tartalmazó gyógyszerkészítmény
RU2005131578A (ru) Аплидин для лечения множественной миеломы
NO20052313L (no) Vandig farmasoytisk formulering omfattende trombininhibitorer melagatran og anvendelse av formuleringen for fremstilling av et medikament for anvendelse i nasal administrering i behandling av
BR9508021A (pt) Composição farmacêutica para o tratamento de distúrbios esquizofrênicos, uso de um agente imunossupressor, e, processo de tratamento de um paciente esquizofrênico

Legal Events

Date Code Title Description
FB Suspension of granting procedure